A carregar...
Publicação
Drug desensitizations for chemotherapy: safety and efficacy in preventing anaphylaxis
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 2.17 MB | Adobe PDF |
Orientador(es)
Resumo(s)
Hypersensitivity reactions (HSRs) to antineoplastic drugs are increasing due to the expanding use of classical and new drugs in a wide variety of malignancies. PURPOSE OF REVIEW: The goal of this review is to provide current best practices in the diagnosis and management of HSRs based on data and evidence. RECENT FINDINGS: A plethora of studies have provided evidence of the safety and efficacy of rapid drug desensitizations (RDD) to allow for the reintroduction of antineoplastic drugs following an HSR, based on risk stratification. Recently described biomarkers such as basophil activation test, total IgE, BRCA genotyping, and serum IL-6 can aid in guiding improved precision desensitization protocols. Personalized premedication regimens and protocols have improved RDD safety and outcomes. RDD allows for the continued use of chemotherapeutic drugs without impaired drug efficacy. RDD represents the best approach to maintain cancer patients on their most effective treatments.
Descrição
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021
Palavras-chave
Chemotherapy Endophenotypes Hypersensitivity reactions Monoclonal antibodies Rapid drug desensitization Risk stratification
Contexto Educativo
Citação
Curr Allergy Asthma Rep. 2021 Jul 7;21(6):37
Editora
Springer Nature